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1 Department of Animal and Food Sciences, Texas Tech University, Lubbock, TX, USA, 2 Hanwoo Research Institute, National
Institute of Animal Science, Rural Development Administration, Kangwon, South Korea, 3 Kemin Animal Nutrition and Health
North America, Des Moines, IA, USA
In vitro experiments were performed to determine the effects of increasing concentrations
of chromium propionate (CrPro) on mRNA and protein abundance of different enzymes
and receptors. Intramuscular (IM) and subcutaneous (SC) preadipocytes and bovine
satellite cells were isolated from the longissimus muscle to determine the effect of
treatment on glucose transporter type 4 (GLUT4) and peroxisome proliferator-activated
receptor γ mRNA and GLUT4 protein abundance. Preadipocyte cultures were treated
with differentiation media plus either sodium propionate or different concentrations of
CrPro for 96, 120, and 144 h before harvest. This study indicated that adipogenesis of
the bovine IM adipocytes were more sensitive to the treatment of CrPro as compared
to SC adipocytes. Enhancement of adenosine monophosphate-activated protein kinase
and GLUT4 mRNA by CrPro treatment may enhance glucose uptake in IM adipocytes.
CrPro decreased GLUT4 protein levels in muscle cell cultures suggesting that those
cells have increased efficiency of glucose uptake due to exposure to increased levels
of CrPro. In contrast, each of the two adipogenic lines had opposing responses to
the CrPro. It appeared that CrPro had the most stimulative effect of GLUT4 response
in the IM adipocytes as compared to SC adipocytes. These findings indicated oppor-
tunities to potentially augment marbling in beef cattle fed CrPro during the finishing
phase.
Keywords: beef cattle, chromium, GLUT4, marbling
Introduction
It has been generally accepted that chromium (Cr) potentiates the effects of insulin (1). Chromium,
included in the diet as KemTRACE®brand Chromium Propionate 0.04% (KT Cr), has improved the
performance of beef cattle. These improvements have been expressed as additional body weight
gain, better feed efficiency, lower morbidity, and mortality (2–4). Initial results from studies with
feeder cattle suggest that feeding KTCr also has positive effects on immune response, cytokines, and
acute phase response of cattle to stress (5). The potential effects of improved glucose metabolism on
carcass characteristics have shown mixed results (2, 4). The effect of chromium propionate (CrPro)
on bovine muscle, intramuscular (IM) adipose, and subcutaneous (SC) adipose tissue development
is unknown. This research was conducted to further investigate the effects of CrPro on enhancing
adipogenic differentiation of bovine muscle derived cells, IM, and SC adipocytes.
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Materials and Methods
Preadipocyte and Satellite Cell Isolation
From Tissues
Bovine muscle satellite cells (BSC) and preadipocytes were iso-
lated from four 16-month-old BritishContinental crossbred
steers. Cattle were harvested by captive bolt followed by exsan-
guination. All experimental procedures were approved by the
Texas Tech University Institutional Animal Care and Use Com-
mittee, and performed at the Texas Tech University Beef Cattle
Research Center. Immediately after hide removal, a section of
the longissimus muscle was removed from between the fifth and
eighth thoracic ribs and transported to the cell culture laboratory.
The following procedures were conducted in a sterile field under a
tissue culture hood. For BSC isolation, connective and adipose tis-
sueswere removed from themuscle sample (Figure 1). Themuscle
sample was passed through a sterile meat grinder. The ground
muscle was incubated with 0.1% pronase (Calbiochem, La Jolla,
CA, USA) in Earl’s Balanced Salt Solution (Sigma, St. Louis, MO,
USA) for 1 h at 37°C with mixing every 10min. The mixture was
centrifuged at 1,500 g for 4min at room temperature following
incubation. The pellet that was formed during centrifugation was
suspended in phosphate buffered saline (PBS; Invitrogen, Grand
Island, NY, USA; 140mM NaCl, 1mM KH2PO4, 3mM KCl,
8mM Na2HPO4), and the suspension was centrifuged at 500 g
at 20°C for 10min. The supernatant was collected and centrifuged
at 1,500 g for 10min at 20°C to pellet the mononucleated cells.
Two additional PBS washes and differential centrifugations were
conducted before the resulting mononucleated cell preparation
was suspended in cold (4°C) Dulbecco’s Modified Eagle Medium
(DMEM; Invitrogen) containing 10% fetal bovine serum (FBS;
Invitrogen) and 10% (vol/vol) dimethylsulfoxide (Sigma, St. Louis,
MO). Cells were stored frozen in liquid nitrogen for future use.
The IM and SC adipose tissues were separated from the mus-
cle, finely minced, and placed in separate containers containing
isolation buffer, which consisted of DMEM, collagenase (Sigma,
St. Louis, MO, USA), and bovine serum albumin (BSA; Sigma
St. Louis, MO, USA). The containers were then incubated in a
shaking incubator for 40min at 38°C. Following incubation, the
isolation buffers containing the IM or SC adipose tissue samples
were passed through sterilized nylon mesh. Samples were then
centrifuged for 5min at 1,500 rpm. Supernatant was removed and
the cell pellet was suspended in 20mL of warm (37°C) DMEM
containing 10% FBS. The centrifugation step was repeated two
additional times before the resulting cell pellet was suspended
in cold (4°C) DMEM containing 10% FBS and 10% (vol/vol)
dimethylsulfoxide. Cells were stored frozen in liquid nitrogen for
future use.
Differentiation of BSC and Preadipocyte Cultures
Bovine satellite cells and the IM and SC preadipocyte cultures
were plated in DMEM containing 10% FBS. Bovine satellite cell
cultures were rinsed with DMEM with 10% FBS at 24 and 72 h
of incubation. At 120 h of incubation, the BSCs were treated
with differentiation media containing 3% horse serum (Sigma,
St. Louis, MO, USA), 1.5μg/mL of BSA-linoleic acid, and one
of five treatments. The treatments for the BSC were as follows:
(1) control, (2) 0.1μM CrPro (Kemin Animal Nutrition and
Health North America, Des Moines, IA, USA), (3) 1μM CrPro,
(4) 10μM CrPro, (5) 10μM sodium propionate (NaPro; Sigma,
St. Louis, MO, USA). Chromium for this study was prepared
from KemTRACE®brand CrPro base (lot # 1006101421), assayed
to contain 8.59% Cr. A 100μM solution was prepared from the
above base and was utilized in this in vitro study.
Intramuscular and SC preadipocyte cultures were incubated
until cells reached approximately 100% confluence. When 100%
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SC preadipocyte 
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Proliferation (10%FBS/DMEM) Differentiation with treatments 
Harvest Confluence Subculture 
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FIGURE 1 | Time frames of bovine intramuscular (IM) and subcutaneous (SC) preadipocyte differentiation in primary cell culture. These intramuscular
and subcutaneous adipocytes showed different patterns of accumulated lipid droplets. FBS, fetal bovine serum; DMEM, Dulbecco’s modified eagle medium.
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confluence was achieved, cultures were rinsed three times with
serum-free DMEM and DMEM containing 5% FBS plus treat-
ments were added for 96, 120, or 144 h. The treatments for
IM and SC preadipocyte cultures were as follows: (1) control,
(2) 1μM CrPro, (3) differentiation media, (4) differentiation
media+ 0.1μM CrPro, (5) differentiation media+ 1μM CrPro,
(6) differentiation media+ 10μM CrPro, and (7) differentiation
media+ 10μM NaPro. The differentiation media used in treat-
ments 3–7 consisted of 10μM ciglitizone (Sigma, St. Louis, MO,
USA), 100μM oleic acid (Sigma, St. Louis, MO, USA), 1μM
dexamethasone (Sigma, St. Louis, MO, USA), and 10μM insulin
(Sigma, St. Louis, MO, USA). Oil-Red-O and hematoxylin stain-
ing were used to confirm the accumulation of lipid droplets in
differentiated BSC and IM and SC preadipocyte cultures. The cells
were fixed with 10% neutral buffer formalin. After fixation, the
cultures were stained with 0.5% Oil-Red-O solution in darkness.
Following Oil-Red-O staining, cultures were stained with Harris’
hematoxylin for 30min in darkness. Cell cultures were mounted
in 60% propylene glycol and stored for analysis. IM and SC
adipocytes were identified by the presence of lipid droplets in the
cytosol, which were changed to a red color by Oil-red-O staining,
and hematoxylin staining, which stained the nuclei of cells, was
used to identify the multinucleated myotubes of differentiated
muscle cells.
Real-Time Quantitative-PCR
RNA from cultured BSC and preadipocytes (IM and SC) were
isolated with 500μL of ice-cold buffer containing TRI reagent
(Sigma, St. Louis, MO, USA). Concentration of RNA was deter-
mined by absorbance at 260 nm. Real-time quantitative-PCR
(RTQ-PCR) was used to measure the quantity of glucose trans-
porter type 4 (GLUT4), CCAAT/enhancer-binding protein β
(C/EBPβ), peroxisome proliferator-activated receptor γ (PPARγ),
stearoyl-CoA desaturase (SCD), and G protein coupled recep-
tor 43 (GPR43) mRNA relative to the quantity of riboso-
mal protein subunit 9 (RPS9) mRNA in total RNA isolated
from BSC and preadipocyte cultures. The quantity of adeno-
sinemonophosphate-activated protein kinase (AMPKα), GLUT4,
myosin heavy chain (MHC)-I, MHC-IIa, and MHC-IIX, β1-
adernergic receptor (AR), and β2-AR relative mRNA was mea-
sured relative to the quantity of RPS9 in total RNA isolated from
the bovine satellite cells. Assays were performed in the GeneAmp
7900H Sequence Detection System (Applied Biosystems) using
thermal cycling parameters recommended by the manufacturer
(40 cycles of 15 s at 95°C and 1min at 60°C). The endogenous
RPS9 mRNA control was used to normalize the expression of
GLUT4, PPARγ, C/EBPβ, SCD, and GPR43.
Western Blotting
Protein from cultured BSC and preadipocytes (IM and SC) was
isolated with 200μL of ice-cold buffer containing M-PER (Fisher
Scientific, Fair Lawn, NJ, USA), protein inhibitor (Roche, Indi-
anapolis, IN, USA), and 2mM Na3VO4 (Fisher Scientific). Cell
homogenates were mixed with an equal volume of 2 standard
SDS sample loading buffer (Invitrogen) and loaded onto gels. Gra-
dient gels (10–20%) were used for SDS-PAGE separation of pro-
teins. Membranes were incubated overnight at 4°C with primary
antibodies (Abcam, Cambridge,MA, USA) at a dilution of 1:1,000
in TBS-Tween. Membranes were then incubated with horseradish
peroxidase-conjugated secondary antibodies at 1:2,000 dilution
for 2 h. After three 10-min washes, membranes were visualized
using enhanced chemiluminescent substrate (ECL) Western blot-
ting reagents (Amersham Bioscience, Piscataway, NJ, USA) and
exposure to film (MR, Kodak, Rochester, NY, USA). Density of
bands was quantified using Imager Scanner II and ImageQuant
TL software. To reduce the variation between blots, tissue lysates
of both groups were run in a single gel. Band density was normal-
ized according to the glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) content.
Statistical Analysis
Data were analyzed as a complete randomized block design using
theMixed procedure (PROCMIXED) of SAS (SAS Institute, Cary,
NC, USA). Differences between control and treatment were deter-
mined using the least significant difference procedure. Means
were considered significantly different at P< 0.05.
Results
The first experiment used RTQ-PCR analysis of IM and SC
adipocytes to examine the effect of a 96 h-treatment of CrPro
on preadipocyte differentiation. RTQ-PCR analysis of IM cells
revealed that 10μM CrPro increased AMPKα, PPARγ mRNA,
and GLUT 4 abundance compared to all other treatments
(Figure 2).
These data indicated that the highest dose of CrPro (10μM)
enhanced IM preadipocyte differentiation as evidenced by the
increased PPARγ mRNA levels whereas the SC preadipocytes
were non-responsive to CrPro in regards to PPARγ concentra-
tions. SC adipocytes treated with 10μM CrPro had an increased
AMPKα mRNA abundance compared to 0.1 and 1μM CrPro
treatments, but did not differ from the differentiated control
cultures (Figure 2). To verify that these differences between IM
and SC adipocytes were a result of Cr and not its carrier, propi-
onate (Pro), a second experiment was conducted with additional
treatments.
In the second experiment, an addition of a 10μM NaPro
treatment helped to verify that the effects previously seen were
due to the addition of elemental Cr rather than an effect of
Pro. Furthermore, IM and SC adipocytes were differentiated
with their respective treatments for 96, 120, or 144 h to observe
potential time course effects throughout differentiation. Morpho-
logical analysis of these cells revealed that primary cultures of
preadipocytes treated with the adipogenic differentiation cocktail
accumulated lipid droplets in the cell cytosol after 96 h (Figure 1).
Lipid droplets in the IM and SC preadipocyte cultures increased
in a dose-dependent manner when treated with CrPro compared
to the control and NaPro treatments (Figure 3). However, our
qualitative data suggest that a higher dose of Cr may be required
to activate lipid filling of IM adipocytes as compared to SC
adipocytes as indicated in Figure 4. Morphological analysis for
BSC (muscle cells) revealed that treatment of CrPro appeared to
increase abundance and diameter of myotubes compared to the
control and NaPro-treated cultures (Figure 3). These data would
indicate a positive effect on skeletal muscle hypertrophy (size of
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FIGURE 2 | The effect of dose-dependent treatment of chromium
propionate (CrPro) on mRNA abundance of key genes regulating
differentiation in intramuscular (IM; left) and subcutaneous (SC; right)
adipocytes at 96h post treatment. Chromium propionate regulated mRNA
levels of adenosine monophosphate-activated protein kinase (AMPKα),
CCAAT/enhancer-binding protein β (C/EBPβ), glucose transporter type 4
(GLUT4), G protein coupled receptor 43 (GPR43), peroxisome
proliferator-activated receptor γ (PPARγ), and stearoyl-CoA desaturase (SCD) in
the IM and SC adipocytes cultures in a dose-dependent fashion. Assays per
treatment, n=3. Treatments with different superscripts differ at P<0.05.
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Intramuscular Adipocytes 
Subcutaneous Adipocytes 
Control 0.1 µM CrPr 1 µM CrPr 10 µM CrPr 10 µM NaPr 
Control 0.1 µM CrPr 1 µM CrPr 10 µM CrPr 10 µM NaPr 
Muscle Satellite Cells 
Control 0.1 µM CrPr 1 µM CrPr 10 µM CrPr 10 µM NaPr 
FIGURE 3 |Morphological analysis of dose-dependent treatment of
chromium propionate (CrPro) in intramuscular (IM), subcutaneous
(SC) adipocyte, and satellite cell cultures at 96h post treatment. Lipid
droplets were stained with Oil-Red-O and nuclei were stained with
hematoxylin. Increasing Cr dose on IM adipocytes increases lipid droplet
numbers. Lipid droplets increase in SC adipocytes up to 1μM CrPr.
Increasing Cr dose in muscle satellite cells results in increasing muscle fiber
size and number.
myotubes) and differentiation (extent and number of myotubes)
caused by CrPro addition to these primary cultures of muscle
satellite cells.
No difference was detected between differentiation media and
CrPro-treated adipocytes and in AMPKα mRNA abundance for
either the IM or SC adipocytes at 96, 120, or 144 h (Figures 4
and 5). At 144 h in SC cultures, adipocytes treated with differ-
entiation media plus 0.1 or 1μM CrPro had a greater PPARγ
mRNAabundance (P< 0.01) compared to adipocytes treatedwith
differentiation media (Figure 5). However, the highest dose was
not different from negative control. Again, these data indicated
that a lower dose of CrPro may stimulate differentiation of SC
preadipocytes while IM preadipocytes require a higher dose. The
relative abundance of GLUT 4 mRNA at 144 h was not differ-
ent between differentiation media and CrPro-treated cultures in
either IM or SC adipocytes (Figures 4 and 5). Additionally, there
was no effect on GPR43, and SCDmRNA relative abundance due
toCrPro addition in either IMor SC adipocytes at 144 h (Figures 4
and 5). However, there was increased (P< 0.01) PPARγ mRNA
relative abundance when differentiation media was added to the
cultures, which indicated that cells underwent normal differentia-
tion in our culture system. In SC adipocytes treated with CrPro or
NaPro, no significant differences in GLUT4 protein were detected
(Figure 6). However, 0.1μM CrPro treatment tended (P= 0.10)
to increase the GLUT4 protein level in IM adipocytes compared
to NaPro treatment (Figure 6).
In the third experiment, BSCs were used to determine the
effect of chromium on muscle cells. No differences (P> 0.10)
in mRNA relative abundance were observed when CrPro or
NaPro treatments were added to the media for AMPKα, GLUT
4, MHC I, MHC-IIa, MHC-IIx, β1-AR, and β2-AR expression
(Figure 7). However, Western blot analysis of BSC indicated that
the protein abundance of GLUT4 relative to GAPDH significantly
decreased (P< 0.01) in a dose-dependent manner as increased
concentrations of chromiumwere added to the BSC culturemedia
(Figure 8). These data are very interesting and suggest a potential
negative feedbackmechanism onGLUT4 protein due to enhanced
efficiency of glucose uptake regulated byCr in amuscle cell culture
system.
Discussion
The results from this study indicated that the treatment of cells
with CrPro altered mRNA levels of adipogenic and metabolic
markers, as well as inducing morphological changes in bovine
muscle cells and preadipocytes. Chromium addition had diver-
gent effects in the three different cell types. In IM adipocytes,
the NaPro treatment had less lipid droplets compared to the dif-
ferentiation treatment indicating that chromium itself enhances
adipocyte differentiation rather than propionate. Oil-red-O
stained images of these treatments indicated that multilocular
lipid droplets accumulated in IM preadipocytes compared to the
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FIGURE 4 | Chromium propionate (CrPro) regulated mRNA levels of
adenosine monophosphate-activated protein kinase (AMPKα ),
CCAAT/enhancer-binding protein β (C/EBPβ ), glucose transporter type
4 (GLUT4), G protein coupled receptor 43 (GPR43), peroxisome
proliferator-activated receptor γ (PPARγ ), and stearoyl-CoA desaturase
(SCD) in the intramuscular (IM) adipocytes cultures. Treatments: (1) 5%
fetal bovine serum/Dulbecco’s Modified Eagle Medium (FBS/DMEM; Cont);
(2) Cont+ 1μM CrPro; (3) differentiation media (Diff; 5% FBS/DMEM, 10μg/mL
insulin,1.0μg/mL dexamethasone, 10μM ciglitizone, 100μM oleic acid; Diff);
(4) Diff+ 0.1μM CrPro; (5) Diff+ 1μM CrPro; (6) Diff+ 10μMCrPro;
(7) Diff+ 10μM NaPro. abcWithin time period, treatments with different
superscripts differ (P<0.05).
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FIGURE 5 | Chromium propionate (CrPro) regulated mRNA levels of
adenosine monophosphate-activated protein kinase (AMPKα ),
CCAAT/enhancer-binding protein β (C/EBPβ ), glucose transporter
type 4 (GLUT4), G protein coupled receptor 43 (GPR43), peroxisome
proliferator-activated receptor γ (PPARγ ), and stearoyl-CoA desaturase
(SCD) in the subcutaneous (SC) adipocytes cultures. Treatments: (1) 5%
fetal bovine serum/Dulbecco’s Modified Eagle Medium (FBS/DMEM; Cont);
(2) Cont+ 1μM CrPro; (3) differentiation media (Diff; 5% FBS/DMEM, 10μg/mL
insulin, 1.0μg/mL dexamethasone, 10μM ciglitizone, 100μM oleic acid; Diff);
(4) Diff+ 0.1μM CrPro; (5) Diff+ 1μM CrPro; (6) Diff+ 10μMCrPro;
(7) Diff+ 10μM NaPro. abcWithin time period, treatments with different
superscripts differ (P<0.05).
Frontiers in Veterinary Science | www.frontiersin.org September 2015 | Volume 2 | Article 267
Tokach et al. Chromium and preadipocytes
0
10
20
30
40
50
Diff NaPro 0.1μM 
CrPro
10μM 
CrPro
0
10
20
30
40
50
Diff NaPro 0.1μM 
CrPro
10μM 
CrPro
Diff NaPr .1 CrPro 10 CrPro 
GLUT 4 
β-Actin 
Diff NaPr .1 CrPro 10 CrPro 
IM SC 
FIGURE 6 | Effects differentiation media (Diff), chromium propionate
(CrPro), and sodium propionate (NaPro) on glucose transporter type 4
(GLUT4) protein abundance (n= 3). Protein was isolated from bovine
intramuscular and subcutaneous adipocytes after 96 h of treatment, and protein
abundance was determined through western blot analysis. Bars represent the
standard error of the difference between the treatment means.
unilocular lipid droplets that accumulated in the SC preadipocytes
at 96 h. The different distribution of lipid droplets indicates a
basic morphological difference between IM and SC adipocytes
and shows that the cell culture model was accurate in distin-
guishing the two cell types. Smith and Crouse demonstrated that
IM and SC adipose tissues had metabolic differences (6). They
also showed that the proportion of carbon provided by glucose
for bovine adipocyte development decreased from 65% in IM
adipose tissue and from 22% in SC adipose tissue. These find-
ings suggested that glucose is a more important source for IM
adipose development than SC adipose development. In contrast,
acetate is a more important source for SC adipose tissue develop-
ment than for IM adipose tissue development. Themorphological
differences between IM and SC adipocytes may be regulated
by these metabolic differences. In IM adipoctyes, the number
of lipid droplets increased as the dose of CrPro was increased.
Interestingly, in SC adipocytes, the number of lipid droplets also
increased as the dose of CrPro was increased up to 1μM CrPro.
However, SC adipocytes treated with 10μM CrPro had less lipid
droplets that SC adipocytes treated with 1μM CrPro. This sug-
gests that in SC adipocytes, CrPro concentration above 1μM
CrPro may begin to have a negative effect on adipocyte devel-
opment. The data also suggested that a higher dose is required
in IM preadipocyte to get maximal glucose uptake in these cells.
The GLUT4 data supported this concept due to an apparent
positive effect of CrPro on Glut4 protein in IM preadipocytes
but no effect in SC preadipocytes. Taken together, these data
indicated that IM adipocytes are more sensitive to Cr from a
glucose regulation standpoint as compared to SC adipocytes. Bio-
logically, this makes sense since IM cells require glucose as the
energy substrate whereas SC adipocytes can synthesize lipids from
acetate (6).
Adipogenic markers, such as PPARγ, were also differen-
tially expressed for IM compared to SC adipocytes. Peroxisome
proliferator-activated receptor γ is involved in gene regulation and
its transcriptional activity is stimulated by insulin (7). The upregu-
lation of PPARγ that results from this stimulation can increase the
cellular uptake of fatty acids and enhance adipocyte development
(8). In the first experiment, treatment with 10μM CrPro upregu-
lated PPARγmRNAexpression in IMadipocytes at 96 h compared
to all other treatments. This mirrored the morphological changes
seen in the IM adipocytes where an increasing dosage of CrPro
resulted in an increase in lipid droplet number. In the second
experiment, 0.1 and 1μM CrPro-treated SC adipocytes had a
higher PPARγ mRNA expression than the differentiated control
SC adipocytes at 144 h. However, at 144 h in the SC adipocytes,
the 10μMCrPro-treated samples were not different from controls
in PPARγ mRNA expression. Again, this mirrored the morpho-
logical changes observed in SC adipocytes. In the SC adipocytes,
an increasing dose of CrPro, up to 1μM, is beneficial to lipid
droplet number. However, CrPro treatment in excess of 1μM
appears to cause a decline in lipid droplet number and as a result,
could hinder adipocyte development. Together, these effects of
CrPro on PPARγ and lipid droplet number suggested that higher
concentrations of CrPro may be used to enhance IM adipocyte
development without augmenting SC adipocyte development.
Adenosine monophosphate-activated protein kinase α, which
regulates cellular energy balance, is an important enzyme in
regulating lipid metabolism not only in adipocytes but also in
BSC. Activation of AMPKα in muscle and adipose tissue triggers
metabolic changes, such as the switch from storing to consuming
fats and carbohydrates. Phosphorylation of AMPKα has been
shown to be positively correlated with GLUT4 activity, which
regulates glucose entry into muscle and adipose tissue (9). In
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FIGURE 7 | Effect of differentiation media (Diff), chromium propionate
(CrPro), and sodium propionate (NaPro) on adenosine
monophosphate-activated protein kinase (AMPKα ), glucose transporter
type 4 (GLUT4), myosin heavy chain (MHC)-I, MHC-IIa, and MHC-IIX,
β1-adernergic receptor (AR), and β2-AR mRNA levels in bovine satellite
cells (n= 3). Bars represent the standard error of the difference between the
treatment means. There was no effect (P>0.10) of treatment on the mRNA
expression of AMPKα, GLUT4, MHC I, MHC-IIa, MHC-IIx, β1-AR, or β2-AR.
experiment 1 at 96 h, relative AMPKαmRNA levels isolated from
IM adipocyte increased with the 10μMCrPro treatment but were
not different from differentiated controls in SC adipocytes. This
indicated that the level of AMPKα can be regulated by treatment
with CrPro. These data suggest that enhancement of AMPKα by
CrPro treatment may improve glucose uptake in IM adipocytes.
In the third experiment, a comparison of the BSC micrographs
of 0.1μMCrPro to either 1 or 10μMCrPro revealed that therewas
a qualitative effect of CrPro on BSC cultures. The BSC cultures
treated with CrPro appeared to have a greater myotube number
and diameter compared to the control cultures. The difference in
myotube sizemay be a result of increased energy or glucose uptake
by those cultures, resulting in larger myotubes. In vivo, these
differences would be manifested as changes in postnatal muscle
hypertrophy. Again, this would be positive to muscle growth,
especially during the feeding of a beta-adrenergic agonist, the last
part of the feeding period. This combination of larger myotubes
and the decreased GLUT4/GAPDH protein ratio may suggest
that CrPro is causing muscle tissue to be much more efficient at
glucose uptake, so the cell actually needs less GLUT4 to take up
the same amount of glucose. Since increased myotube number
and diameter were still detected, the glucose transporters may be
also more efficient with treatment of CrPro. This would explain
why mRNA did not change and protein abundance decreased,
but morphological effects were still observed. However, the IM
preadipocytes normally need to compete with skeletal muscle for
glucose in ruminants. Our data indicated that CrPro actually stim-
ulated GLUT4 in those cells in means to more effectively compete
with skeletal muscle tissue for glucose. In fact, our dose titration
work suggested that higher the dose, the more effect on glucose
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FIGURE 8 | Effect of differentiation media (Diff), chromium propionate
(CrPro), and sodium propionate (NaPro) on glucose transporter type 4
(GLUT4)/glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
protein abundance (n= 4). Protein was isolated from bovine satellite cells
after 72 h of treatment and protein abundance was determined through
western blot analysis. Bars shown represent the standard error of the
difference between the treatment means. Bars with different letters differ
(P<0.01).
metabolism and lipid filling in IM preadipocytes. In contrast,
CrPro had little effect on glucose transport in SC preadipocytes.
This makes sense since they do not require glucose to synthesize
lipids and can rely on acetate.
Chromium, a trace mineral required for insulin action, reg-
ulated mode of action of insulin signaling and has been shown
to induce glucose absorbance in the muscle and adipocytes (10).
Chromium Pro and Cr methionine have also been reported to
inducing glucose uptake and feed intake (11). This study indi-
cated that a dose-dependent Cr supplementation increased glu-
cose level, decreased insulin, and non-esterified fatty acids in
the serum. Recent data indicated that pharmacological doses of
Cr appear to increased insulin sensitivity in rodent study and
the mode of action of Cr could serve in a regulation of second
messenger in animals (12). These data also indicated that trans-
ferrin is a major agent as physiological Cr transport in blood-
stream. The receptor-specific regulation of transferrin is sensitive
to insulin and it results in a stimulation of inorganic second
messenger in plasma membrane. Therefore, CrPro likely induces
glucose utilization through insulin signaling for growing cattle.
Our data indicated that a time-dependent treatment of CrPro
increased GLUT4 levels in IM adipocyte cultures. These GLUT4
data indicated that treatment of CrPro may be regulating the early
phase of IM adipocyte differentiation. The level of GLUT4 was
steadily increased in both IM and SC adipocytes during the late
phase of adipocyte differentiation. However, bovine satellite cells
treated with CrPro in this study showed no effect on GLUT4
mRNA expression and had decreased GLUT4/GAPDH protein
ratio in a dose-dependent fashion. The variation in these results
between adipocytes and muscle satellite cells indicated that CrPro
has differential effects on different tissues. In essence, the CrPro
decreased GLUT4 protein levels in muscle cell cultures (Figure 8)
indicating that those cells have increased efficiency of glucose
uptake due to exposure to increased levels of CrPro. In contrast,
each of the two adipogenic lines had opposing responses to the
CrPro. It appeared that CrPro had the most stimulative effect
of GLUT4 response in the IM adipocytes as compared to SC
adipocytes. This suggests opportunities to potentially augment
marbling in beef cattle fed elevated levels of CrPro during the
finishing period. In addition, skeletal muscle growth could be
further enhanced in cattle being fed both a beta-adrenergic agonist
and CrPro the last 20–40 days on feed.
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